Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1936-1945

  Rattanasompattikul, Manoch ^a,g   Molnar, Miklos Z ^a,b,c   Zaritsky, Joshua J ^d   Hatamizadeh, Parta ^a   Jing, Jennie ^a   Norris, Keith C ^e   Kovesdy, Csaba P ^f,g   Kalantar Zadeh, Kamyar ^a,h  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Erythropoietin stimulating agent (ESA) therapy; Hemoglobin; Inflammatory marker; Malnutrition inflammation complex; Responsiveness to ESAs

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; INTERLEUKIN 6; IRON; PARATHYROID HORMONE; PREALBUMIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; HEMODIALYSIS; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LONG TERM CARE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION INFLAMMATION COMPLEX; MALNUTRITION INFLAMMATION SCORE; METABOLIC PARAMETERS; NEGRO; PHYSICAL DISEASE BY ETIOLOGY AND PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCORING SYSTEM; TRANSFERRIN SATURATION;

ERYTHROPOIETIN-STIMULATING AGENT (ESA) THERAPY; HEMOGLOBIN; INFLAMMATORY MARKER; MALNUTRITION-INFLAMMATION COMPLEX; RESPONSIVENESS TO ESAS;

ANEMIA; BIOLOGICAL MARKERS; ERYTHROPOIESIS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MALNUTRITION; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS;

EID: 84884515881     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs368     Document Type: Article

References (66)

1. Kalantar-Zadeh K, Kopple JD, Block G et al. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38: 1251-1263
2. Kaizu Y, Ohkawa S, Odamaki M et al. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 2003; 42: 295-302
3. Maruyama Y, Nordfors L, Stenvinkel P et al. Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end-stage renal disease. Blood Purif 2005; 23: 384-393
4. Balakrishnan VS, Guo D, Rao Met al. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 2004; 65: 1449-1460
5. Raj DS, Dominic EA, Pai A et al. Skeletal muscle, cytokines, and oxidative stress in end-stage renal disease. Kidney Int 2005; 68: 2338-2344
6. Caglar K, Peng Y, Pupim LB et al. Inflammatory signals associated with hemodialysis. Kidney Int 2002; 62: 1408-1416
7. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149
8. Eustace JA, Astor B, Muntner PM et al. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 2004; 65: 1031-1040
9. Fujino Y, Ishimura E, Okuno S et al. C-reactive protein is a significant predictor of decrease in fat mass in hemodialysis patients. Biomed Pharmacother 2005; 59: 264-268
10. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391-398
11. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(5 Suppl 3): S11-S145
12. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132
13. Vlagopoulos PT, Tighiouart H, Weiner DE et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005; 16: 3403-3410
14. Messana JM, Chuang CC, Turenne M et al. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model. Am J Kidney Dis 2009; 53: 503-512
15. Rossert J, Gassmann-Mayer C, Frei D et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007; 22: 794-800
16. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 2008: S75-S81
17. Kausz AT, Solid C, Pereira BJ et al. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? Am J Kidney Dis 2005; 45: 136-147
18. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
19. Kaysen GA, Muller HG, Ding J et al. Challenging the validity of the EPO index. Am J Kidney Dis 2006; 47: 166
20. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876
21. Bradbury BD, Brookhart MA, Winkelmayer WC et al. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis 2009; 54: 554-560
22. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568
23. Kalantar-Zadeh K, Kleiner M, Dunne E et al. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 1998; 31: 263-272
24. Stenvinkel P, Barany P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 2002; 17(Suppl 5): 32-37
25. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001; 38: 1343-1350
26. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808. Review. PubMed PMID: 12631061
27. Wei M, Bargman JM, Oreopoulos DG. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol 2007; 39: 935-940
28. Bradbury BD, Critchlow CW, Weir MR et al. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 2009; 24: 919-925
29. Colman S, Bross R, Benner D et al. The Nutritional and Inflammatory Evaluation in Dialysis patients (NIED) study: overview of the NIED study and the role of dietitians. J Ren Nutr 2005; 15: 231-243
30. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
31. Kalantar-Zadeh K, Lee GH, Miller JE et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009; 53: 823-834
32. Gunnell J, Yeun JY, Depner TA et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72
33. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
34. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565
35. Erbagci AB, Tarakcioglu M, Aksoy M et al. Diagnostic value of CRP and Lp(a) in coronary heart disease. Acta Cardiol 2002; 57: 197-204
36. Pecoits-Filho R, Barany P, Lindholm B et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684-1688
37. Beutler B, Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 1989; 7: 625-655
38. Hodges VM, Rainey S, Lappin TR et al. Pathophysiology of anemia and erythrocytosis. Crit Rev Oncol Hematol 2007; 64: 139-158
39. Cooper AC, Mikhail A, Lethbridge MW et al. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003; 14: 1776-1784
40. Pecoits-Filho R, Heimburger O, Barany P et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212-1218
41. Panichi V, Migliori M, De Pietro S et al. Plasma C-reactive protein in hemodialysis patients: a cross-sectional, longitudinal clinical survey. Blood Purif 2000; 18: 30-36
42. Costa E, Lima M, Alves JM et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008; 28: 268-275
43. Guo CH, Wang CL, Chen PC et al. Linkage of some trace elements, peripheral blood lymphocytes, inflammation, and oxidative stress in patients undergoing either hemodialysis or peritoneal dialysis. Perit Dial Int 2011; 31: 583-591
44. Sayarlioglu H, Erkoc R, Demir C et al. Nutritional status and immune functions in maintenance hemodialysis patients. Mediators Inflamm 2006; 2006: 20264
45. Goicoechea M, Martin J, de Sequera P et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54: 1337-1343
46. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207-1211
47. Kalantar-Zadeh K, Ikizler TA, Block G et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42: 864-881
48. Attallah N, Osman-Malik Y, Frinak S et al. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 2006; 47: 644-654
49. Koc M, Dogan C, Arinsoy T et al. Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. Hemodial Int 2011; 15: 366-373
50. Chiang CK, Yang SY, Peng YS et al. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects. Am J Nephrol 2009; 29: 392-397
51. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207
52. Jonathan E, Derrick B, Emma L et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 2011; 377: 469-476
53. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med 2011; 365: 2098-2109
54. Hingorani AD, Shah T, Kumari M et al. Translating genomics into improved healthcare. BMJ 2010; 341: c5945
55. Elliott P, Chambers JC, Zhang W et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302: 37-48
56. Panichi V, Rosati A, Paoletti S et al. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial. Blood Purif 2011; 32: 7-14
57. Panichi V, Scatena A, Paoletti S et al. Impact of dialysis technique on renal anemia. Contrib Nephrol 2011; 171: 261-265
58. Hsu PY, Lin CL, Yu CC et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients-a prospective cross-over study. J Nephrol 2004; 17: 693-700
59. Schiffl H, Lang SM, Bergner A. Ultrapure dialysate reduces dose of recombinant human erythropoietin. Nephron 1999; 83: 278-279
60. Espat NJ, Copeland EM, Moldawer LL. Tumor necrosis factor and cachexia: a current perspective. Surg Oncol 1994; 3: 255-262
61. McCarthy DO. Tumor necrosis factor alpha and interleukin-6 have differential effects on food intake and gastric emptying in fasted rats. Res Nurs Health 2000; 23: 222-228
62. Kalantar-Zadeh K, McAllister CJ, Lehn RS et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773
63. Stenvinkel P, Heimburger O, Lindholm B et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15: 953-960
64. Kaysen GA, Dubin JA, Muller HG et al. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58: 346-352
65. Jager KJ, Stel VS, Zoccali C et al. The issue of studying the effect of interventions in renal replacement therapy-to what extent may we be deceived by selection and competing risk? Nephrol Dial Transplant 2010; 25: 3836-3839
66. Rothman KJ. Epidemiology: An Introduction. Oxford: Oxford University Press, 2002